论文部分内容阅读
本文26例慢性肺心病的治疗中按照储钾利尿剂(安体舒通)和氯化钾使用方法的不同,分为三组;组Ⅰ安体舒通加氯化钾11例,组Ⅱ单用安体舒通7例,组Ⅲ单用氯化钾8例。比较治疗后三组高钾血症的发生率,组Ⅰ11例均出现高钾血症(100％),组Ⅱ仅一例,组Ⅲ无一例发生。有明显统计学上差异(t=4.82,p<0.001),该结果表明组Ⅰ高钾血症系同时使用安体舒通和氯化钾所致。指出在治疗慢性肺心病过程中,应正确使用保钾利尿剂和钾盐,以防止高钾血症的危险。
In this paper, 26 cases of chronic pulmonary heart disease in accordance with the potassium-storing diuretic (spironolactone) and potassium chloride use is divided into three groups; group Ⅰ spironolactone plus potassium chloride in 11 cases, group Ⅱ single Spironolactone in 7 cases, group Ⅲ only potassium chloride in 8 cases. The incidence of hyperkalemia was compared between the three groups after treatment. All the 11 cases showed hyperkalemia (100%), only one case in group Ⅱ, and none in group Ⅲ. There was a statistically significant difference (t = 4.82, p <0.001), which indicated that both group Ⅰ hyperkalemia combined with spironolactone and potassium chloride. Pointed out that in the treatment of chronic pulmonary heart disease, should be the correct use of potassium sparing diuretics and potassium to prevent the risk of hyperkalemia.